Home
Storia in 2 fonti
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
- ·
benzinga.com
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies - ImmunityBio (NASDAQ:IBRX)
ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key bladder cancer measures.
- ·
morningstar.com
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with…
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for…
- ·
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug - ImmunityBio (NASDAQ
ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer outcomes.